Australia After last year’s acquisition of Vifor Pharma, the firm’s largest ever, opened new avenues for diversification, the ground-breaking approval of the Hemgenix gene therapy for Hemophilia B was an equally significant moment for the company. New CEO Paul MacKenzie continues to pursue further growth for Australia’s largest biopharma company, investing…
Belgium Luc Van Gorp is president of the Christian Mutuality, Belgium’s largest health insurance fund. In a wide-ranging recent conversation with PharmaBoardroom, Van Gorp expanded on some of the key themes in his 2021 book ‘Human Scale: A Plea for Imperfection’ (‘Mensenmaat: Een Pleidooi Voor Imperfectie’ in Dutch), including why innovation…
Greece Managing Director of MSD Greece, Cyprus & Malta Agata Jakoncic, who also serves as president of Greece’s PhRMA Innovation Forum (PIF), draws on her three decades of industry experience to outline some of the key challenges in the Greek pharma market today which threaten its sustainability and the ability of…
MEA Healthcare in the GCC continues to undergo major transformation with the introduction of government reforms, a shifting demographic and mandatory health insurance. These factors along with increased private sector participation and an ongoing infrastructure boom are poised to drive further growth in healthcare spending in the region – up to…
MENA Amira Younes of AbbVie UAE examines how the COVID-19 pandemic highlighted the need for new ways of thinking about delivering regulatory effectiveness and efficiency in the region, and for flexibility from all stakeholders to ensure that therapies continue to reach patients in a timely manner. Most countries in the…
Rare Diseases With February’s Rare Disease Day behind us, it can be easy to forget the impact of these diseases on individuals, their families and care givers, and our communities throughout the other 11 months of the year. But if we – in healthcare, in government and in academia – are to…
USA PhRMA President and CEO Stephen J. Ubl takes aim at the health insurers and pharmacy benefit managers (PBMs) driving medicines costs up in the US, and the Inflation Reduction Act (IRA) which he sees as failing to address the patient affordability conundrum. Ubl calls for a policy framework able to…
Europe The Contract Development and Manufacturing Organization (CDMO) sector has flousished in recent years as Big Pharma has shifted its attention to its core R&D activities and outsourced other supply chain components, including manufacturing, to independent CDMOs. In Europe the CDMO market is expected to reach a revenue of nearly USD…
LatAm Latin America is renowned for its creative geniuses – think footballers like Lionel Messi and Pelé; magical realist authors such as Gabriel García Márquez and Isabel Allende; and ground-breaking artists like Frida Kahlo and Wilfredo Lam. This tradition of creativity permeates the continent’s population, who are well used to dreaming…
India The latest news from the Indian pharma industry, including WHO’s recommendation not to use cough syrup from Marion Biotech after further deaths, Indegene’s expanded presence in Europe, Sun Pharma’s FDA warning and the lab partnership between Sai Life Sciences and Schrödinger. WHO recommends not using Marion Biotech cough syrups…
USA David H. Crean, Managing Partner for Cardiff Advisory, discusses the economic impact of the signing and implementation of the Inflation Reduction Act (IRA) on the biopharmaceutical industry and innovation. America’s biopharmaceutical research companies are researching and developing new medicines to meet unmet needs and continuing research and development even…
USA After Big Pharma lobby groups suffered a major drug pricing blow earlier this year with the passage of the US Inflation Reduction Act (IRA), pharma industry heavyweight AbbVie is withdrawing its membership to leading industry trade groups PhRMA and BIO. AbbVie Bows Out AbbVie is leaving both of the…
See our Cookie Privacy Policy Here